Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
55
PHVS Quote, Financials, Valuation and Earnings
Last price:
$27.81
Seasonality move
:
90.96%
Day range:
$23.80 - $29.67
52-week range:
$11.51 - $29.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.20x
Volume:
3.5M
Avg. volume:
398.3K
1-year change:
48.46%
Market cap:
$1.9B
Revenue:
--
EPS (TTM):
-$3.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
-- | -$0.78 | -- | -3.65% | $41.87 |
|
ARGX
argenx SE
|
$1.1B | $4.11 | 87.13% | 205.62% | $966.95 |
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -5.57% | -135.86% | $97.00 |
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 10.75% | -67.59% | $31.00 |
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 14.37% | -38.51% | $58.48 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
$29.37 | $41.87 | $1.9B | -- | $0.00 | 0% | -- |
|
ARGX
argenx SE
|
$921.80 | $966.95 | $56.8B | 46.86x | $0.00 | 0% | 19.66x |
|
MRUS
Merus NV
|
$96.12 | $97.00 | $7.3B | -- | $0.00 | 0% | 120.82x |
|
PHAR
Pharming Group NV
|
$15.81 | $31.00 | $1.1B | 1,105.59x | $0.00 | 0% | 2.98x |
|
PRQR
ProQR Therapeutics NV
|
$2.01 | $8.88 | $211.7M | -- | $0.00 | 0% | 12.16x |
|
QURE
uniQure NV
|
$25.48 | $58.48 | $1.6B | -- | $0.00 | 0% | 87.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
0.19% | 0.173 | 0.04% | 12.56x |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Pharvaris NV vs. Competitors
-
Which has Higher Returns PHVS or ARGX?
argenx SE has a net margin of -- compared to Pharvaris NV's net margin of 25.88%. Pharvaris NV's return on equity of -63% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.70 $367.6M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About PHVS or ARGX?
Pharvaris NV has a consensus price target of $41.87, signalling upside risk potential of 37.14%. On the other hand argenx SE has an analysts' consensus of $966.95 which suggests that it could grow by 4.9%. Given that Pharvaris NV has higher upside potential than argenx SE, analysts believe Pharvaris NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV8 1 0 ARGXargenx SE16 1 0 -
Is PHVS or ARGX More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock PHVS or ARGX?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or ARGX?
Pharvaris NV quarterly revenues are --, which are smaller than argenx SE quarterly revenues of $948M. Pharvaris NV's net income of -$43.4M is lower than argenx SE's net income of $245.4M. Notably, Pharvaris NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 46.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 19.66x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$43.4M ARGXargenx SE19.66x 46.86x $948M $245.4M
-
Which has Higher Returns PHVS or MRUS?
Merus NV has a net margin of -- compared to Pharvaris NV's net margin of -786.17%. Pharvaris NV's return on equity of -63% beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.70 $367.6M MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About PHVS or MRUS?
Pharvaris NV has a consensus price target of $41.87, signalling upside risk potential of 37.14%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.92%. Given that Pharvaris NV has higher upside potential than Merus NV, analysts believe Pharvaris NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV8 1 0 MRUSMerus NV2 14 0 -
Is PHVS or MRUS More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock PHVS or MRUS?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or MRUS?
Pharvaris NV quarterly revenues are --, which are smaller than Merus NV quarterly revenues of $12.2M. Pharvaris NV's net income of -$43.4M is higher than Merus NV's net income of -$95.5M. Notably, Pharvaris NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 120.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$43.4M MRUSMerus NV120.82x -- $12.2M -$95.5M
-
Which has Higher Returns PHVS or PHAR?
Pharming Group NV has a net margin of -- compared to Pharvaris NV's net margin of 7.71%. Pharvaris NV's return on equity of -63% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.70 $367.6M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About PHVS or PHAR?
Pharvaris NV has a consensus price target of $41.87, signalling upside risk potential of 37.14%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 96.08%. Given that Pharming Group NV has higher upside potential than Pharvaris NV, analysts believe Pharming Group NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV8 1 0 PHARPharming Group NV2 0 0 -
Is PHVS or PHAR More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHVS or PHAR?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or PHAR?
Pharvaris NV quarterly revenues are --, which are smaller than Pharming Group NV quarterly revenues of $96.9M. Pharvaris NV's net income of -$43.4M is lower than Pharming Group NV's net income of $7.5M. Notably, Pharvaris NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,105.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 2.98x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$43.4M PHARPharming Group NV2.98x 1,105.59x $96.9M $7.5M
-
Which has Higher Returns PHVS or PRQR?
ProQR Therapeutics NV has a net margin of -- compared to Pharvaris NV's net margin of -381.88%. Pharvaris NV's return on equity of -63% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.70 $367.6M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About PHVS or PRQR?
Pharvaris NV has a consensus price target of $41.87, signalling upside risk potential of 37.14%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 341.54%. Given that ProQR Therapeutics NV has higher upside potential than Pharvaris NV, analysts believe ProQR Therapeutics NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV8 1 0 PRQRProQR Therapeutics NV7 0 0 -
Is PHVS or PRQR More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.
-
Which is a Better Dividend Stock PHVS or PRQR?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or PRQR?
Pharvaris NV quarterly revenues are --, which are smaller than ProQR Therapeutics NV quarterly revenues of $3.4M. Pharvaris NV's net income of -$43.4M is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, Pharvaris NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 12.16x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$43.4M PRQRProQR Therapeutics NV12.16x -- $3.4M -$12.9M
-
Which has Higher Returns PHVS or QURE?
uniQure NV has a net margin of -- compared to Pharvaris NV's net margin of -2175.87%. Pharvaris NV's return on equity of -63% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.70 $367.6M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PHVS or QURE?
Pharvaris NV has a consensus price target of $41.87, signalling upside risk potential of 37.14%. On the other hand uniQure NV has an analysts' consensus of $58.48 which suggests that it could grow by 129.5%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV8 1 0 QUREuniQure NV9 2 0 -
Is PHVS or QURE More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock PHVS or QURE?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or QURE?
Pharvaris NV quarterly revenues are --, which are smaller than uniQure NV quarterly revenues of $3.7M. Pharvaris NV's net income of -$43.4M is higher than uniQure NV's net income of -$80.5M. Notably, Pharvaris NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 87.06x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$43.4M QUREuniQure NV87.06x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
